At BIO 2019 in Philadelphia, a panel of industry experts discussed their experiences with the FDA's pilot program; ambiguities in drug, device and software pathways; and the hurdles digital health…
Get and save the most relevant links from around the web. Tailored for you.
Or continue with Twitter, Facebook, Google
Already a member? Sign in